Sanofi and Principia agree to develop MS drug candidate
Sanofi will develop Principia Biopharma Inc.'s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous syst...
IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative